Open AccessDetection of Lymphogranuloma Venereum–Associated Chlamydia trachomatis L2 Serovars in Remnant Rectal Specimens Collected from 7 US Public Health Laboratories
Author(s) -
Kai Huang,
Alex de Voux,
Monica Morris,
Samantha S. Katz,
Allan Pillay,
Damien Danavall,
Katherine E. Bowden,
Anne Gaynor,
Ellen N. Kersh
Publication year - 2021
Publication title -
sexually transmitted diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.507
H-Index - 105
eISSN - 1537-4521
pISSN - 0148-5717
DOI - 10.1097/olq.0000000000001483
Subject(s) - lymphogranuloma venereum , chlamydia trachomatis , medicine , serotype , chlamydiaceae , chlamydia , chlamydiales , chlamydial infection , sexually transmitted disease , virology , men who have sex with men , immunology , syphilis , human immunodeficiency virus (hiv)
The frequency of lymphogranuloma venereum or invasive Chlamydia trachomatis infection with serovar L1, L2, or L3 is unknown in the United States. While no diagnostic test is commercially available, we used a laboratory-developed test and detected lymphogranuloma venereum-associated serovar L2 in 14% of 132 remnant C. trachomatis-positive rectal swabs.